TG Therapeutics P/E Ratio Analysis in Relation to Industry Peers
TG Therapeutics has a better P/E ratio of 244.73 than the aggregate P/E ratio of 41.86 of the Biotechnology industry. Ideally, one might believe that TG Therapeutics Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
